Official price cuts and customer pressure to reduce prices
First written in FY2016. 18 of 25 entries say "Restated". Latest entry: FY2025-H1.
OLBA DVx HEALTHCARE moved to the "Worse" side of this theme in 2025, 7 years after the typical company in this theme (2018).
The whole theme swung hardest in 2025: 3 of 8 companies on the "Worse" side.
1 other company's latest entry also says "Materialised".
- FY2025-H1MaterialisedAnnual report
「Revenue from orthopedic consumables continued to decline from the first quarter, mainly because of the impact of the June 2024 reimbursement price revision on spine-related products, and was down 10.9% year on year.」
The impact of the reimbursement price revision has actually emerged as a decline in revenue from spine-related products, with sales of these products down 10.9% from the year-earlier period. - FY2024RestatedAnnual report
「Reimbursement prices are reviewed approximately every 2 years, but tend to be reduced based on prevailing selling prices. In line with this, selling unit prices to medical institutions, the group's primary customers, have also been trending downward, which is a factor putting pressure on profitability.」
The company continues to identify as risks the pressure on profitability from regular reimbursement price reductions and declines in selling unit prices to medical institutions, and indicates that it is responding by improving its purchasing negotiation power and expanding high-value-added products. - FY2024-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risks associated with reductions in regulated prices and customer pressure to lower prices. - FY2024-Q1RestatedAnnual report
「During the first quarter of the current consolidated cumulative period, there were no occurrences of matters that could materially affect investors’ investment decisions among the matters relating to the business and financial position described in this quarterly report, nor were there any material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding reductions in regulated prices and customer pressure to lower prices. - FY2023-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risks associated with reductions in regulated prices and customer pressure to lower prices. - FY2023-Q1RestatedAnnual report
「During the first quarter of the current consolidated cumulative period, there were no occurrences of matters that could materially affect investors’ investment decisions among the matters relating to the business and financial position described in this quarterly report, nor were there any material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risks associated with reductions in regulated prices and customer pressure to lower prices. - FY2022-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes regarding reductions in regulated prices and customer pressure to lower prices. - FY2022-Q1RestatedAnnual report
「During the first quarter of the current consolidated cumulative period, there were no occurrences of matters that could materially affect investors’ investment decisions among the matters relating to the business and financial position described in this quarterly report, nor were there any material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risks associated with reductions in regulated prices and customer pressure to lower prices. - FY2021RestatedAnnual report
「As part of healthcare system reform, reimbursement prices are reviewed approximately every 2 years, but tend to be reduced based on actual selling prices. In line with this, selling prices to medical institutions, the Group's primary customers, are also trending downward, putting pressure on profitability. To address this, the Group is working to improve profitability by strengthening its negotiating power with suppliers and expanding its handling of higher-value-added products.」
The company continues to identify as risks the pressure on profitability from regular reimbursement price reductions and declines in selling unit prices, and indicates that it is responding by improving its purchasing negotiation power and expanding high-value-added products. - FY2020MaterialisedAnnual report
「In addition, the impact of the reduction in reimbursement prices, the government-set prices for medical materials, implemented in October last year was significant, reducing the current-period margin on cardiovascular consumables by approximately 1.0 percentage points year on year.」
The impact of reimbursement price reductions was reflected in the full-year profit margin for cardiovascular consumables, which declined by approximately 1.0 percentage points year on year. - FY2020-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risks associated with reductions in regulated prices and customer pressure to lower prices. - FY2020-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risks associated with reductions in regulated prices and customer pressure to lower prices. - FY2020-Q1RestatedAnnual report
「During the first quarter of the current consolidated cumulative period, there were no occurrences of matters that could materially affect investors’ investment decisions among the matters relating to the business and financial position described in this quarterly report, nor were there any material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risks associated with reductions in regulated prices and customer pressure to lower prices. - FY2019MaterialisedAnnual report
「Cardiovascular consumables were most affected by last year's reimbursement price revision, and revenue decreased 2.3% from the previous fiscal year.」
The impact of the reimbursement price revision emerged as a full-year decline in revenue from cardiovascular consumables, with sales down 2.3% from the previous fiscal year. Meanwhile, catheter ablation products and TAVI-related products expanded. - FY2019-Q3WorsenedAnnual report
「Cardiovascular consumables were most affected by the latest reimbursement price revision, and revenue was limited to 98.7% of the year-earlier level.」
The impact of the reimbursement price revision was particularly pronounced in cardiovascular consumables, with sales in this area reaching 98.7% of the year-earlier level. Growth in catheter ablation products and TAVI-related products is also noted. - FY2019-Q2MitigatedAnnual report
「As a result of implementing various initiatives to address this market environment of medical cost containment, consumables sales reached 101.3% of the year-earlier level, exceeding the prior year by 1.3 percentage points.」
Although the impact of the reimbursement price revision remains significant, consumables sales reached 101.3% of the year-earlier level through various initiatives, improving from 99.6% in the previous quarter. - FY2019-Q1MaterialisedAnnual report
「The reimbursement price revision implemented in April this year was an event with a significant impact on sales of consumables as a whole, which are a growth driver. Although we have undertaken various initiatives to respond to a market environment in which curbing medical costs is considered an important issue, consumables sales were 99.6% of the year-earlier level, 0.4 percentage points below the previous year.」
The reduction in reimbursement prices previously identified as a risk was implemented, and its impact has actually emerged in the form of consumables sales falling below the year-earlier level. The impact of the price revision has been quantified. - FY2018RestatedAnnual report
「Reimbursement prices are reviewed approximately every 2 years, but tend to be reduced based on actual selling prices.」
The company continues to identify as a business risk the tendency for reimbursement prices to be reviewed approximately every 2 years and reduced based on prevailing selling prices. - FY2018-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risks associated with reductions in regulated prices and customer pressure to lower prices. - FY2018-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risks associated with reductions in regulated prices and customer pressure to lower prices. - FY2018-Q1RestatedAnnual report
「During the first quarter of the current consolidated cumulative period, there were no occurrences of matters that could materially affect investors’ investment decisions among the matters relating to the business and financial position described in this quarterly report, nor were there any material changes to the “Business and Other Risks” described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risks associated with reductions in regulated prices and customer pressure to lower prices. - FY2017RestatedAnnual report
「Reimbursement prices are reviewed approximately every 2 years, but tend to be reduced based on actual selling prices.」
The company continues to identify as a business risk the tendency for reimbursement prices for medical materials and other products to be reduced based on prevailing selling prices. - FY2017-Q3RestatedAnnual report
「There were no occurrences of matters relating to the business, financial conditions or other items described in this quarterly report that could have a material impact on investors' decisions during the cumulative third quarter, and no significant changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding reductions in regulated prices and customer pressure to lower prices. - FY2017-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that could materially affect investors’ decisions, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
The company states that there have been no material changes regarding reductions in regulated prices and customer pressure to lower prices. - FY2016First statedAnnual report
「Official prices were reduced by 1.22% for pharmaceuticals and by 0.11% for the medical materials we handle.」
The company states that gross profit margins in its medical equipment business and other operations declined due to reductions in regulated prices resulting from revisions to medical service fees and other factors, as well as customer pressure for discounts.